TLR7 and Splenomegaly: Goel et al. showed that IFNλ was elevated after epicutaneous treatment of a TLR7 agonist, and broadly promoted systemic autoimmune responses as indicated by splenomegaly, increased white blood cells, decreased hemoglobin and platelets, myeloid expansion, neutrophil NET production, and T cell activation [114].